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Abstract
Background: We have previously demonstrated that phenylhexyl isothiocyanate (PHI), a synthetic isothiocyanate,
inhibits histone deacetylases and remodels chromatins to induce growth arrest in HL-60 myeloid leukemia cells in
a concentration-dependent manner.
Methods: To investigate the effect of PHI, a novel histone deacetylases inhibitor (HDACi), on demethylation and
activation of transcription of p15 in acute lymphoid leukemia cell line Molt-4, and to further decipher the potential
mechanism of demethylation, DNA sequencing and modified methylation specific PCR (MSP) were used to screen
p15-M and p15-U mRNA after Molt-4 cells were treated with PHI, 5-Aza and TSA. DNA methyltransferase 1 (DNMT1),
3A (DNMT3A), 3B (DNMT3B) and p15 mRNA were measured by RT-PCR. P15 protein, acetylated histone H3 and
histone H4 were detected by Western Blot.
Results: The gene p15 in Molt-4 cells was hypermethylated and inactive. Hypermethylation of gene p15 was
attenuated and p15 gene was activated de novo after 5 days exposure to PHI in a concentration-dependent
manner. DNMT1 and DNMT3B were inhibited by PHI (P < 0.05). Alteration of DNMT3A was not significant at those
concentrations. Acetylated histone H3 and histone H4 were accumulated markedly after exposure to PHI.
Conclusion: PHI could induce both DNA demethylation and acetylated H3 and H4 accumulation in Molt-4 cells.
Hypermethylation of gene p15 was reversed and p15 transcription could be reactivated de novo by PHI.
Background
The major epigenetic transcriptional controls involved in
gene silencing are DNA methylation and covalent modifi-
cation of histone proteins. Transcriptional silencing of
genes, due to hypermethylation of CpG islands in the pro-
moter region of genes, has been reported in nearly every
type of human tumors. A broad spectrum of genes are fre-
quently hypermethylated in cancers, including those asso-
ciated with cell cycle regulation, detoxification, tumor
suppression, and apoptosis etc. DNA methylation is cata-
lyzed by DNA methyltransferases (DNMTs), of which
three active enzymes have been identified in mammals,
namely DNMT1, DNMT3A and DNMT3B. In develop-
mental processes of the mouse, DNMT1 is responsible for
maintaining pre-existing methylation patterns during
DNA replication, while DNMT3A and DNMT3B are
required for initiation of de novo methylation. DNMT3A
expression is ubiquitous, but DNMT3B is present in the
cells at low levels except in testes, thyroid, and bone mar-
row[1]. DNMTs play roles in gene silencing by acting as
transcriptional repressors themselves, or by serving as
binding scaffolds for transcriptional repressors, histone
deacetylases and histone methyltransferases. Thereby,
DNMTs can establish gene silencing independent of their
catalytic activities[2-4]. In human leukemia cells, the
DNMTs are found to be aberrantly over-expressed[5,6].
Histone proteins assemble into nucleosomes, which func-
tion as both DNA packaging units and transcriptional
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any medium, provided the original work is properly cited.regulators. The amino-terminal tails of histones protrude
from the nucleosome and they are subjected to covalent
modifications such as acetylation, methylation and phos-
phorylation. The different types of histone modifications
have been linked with distinct functions. Modifications to
histones influence chromatin structure, and ultimately
gene transcription, including those coding for tumor sup-
pressor proteins. One of the key histone modification that
control gene transcription is acetylation, which is regu-
lated by two opposing enzymatic activities (histone acetyl-
transferases [HATs] and histone deacetylases [HDACs])
[7]. HATs are in charge of histone acetylation, leading to
the relaxation of chromatin structure and transcriptional
activation of genes, while HDACs are in charge of histone
deacetylation, which is associated generally with chromatin
condensation and transcriptional repression[8].
The gene p15 (INK4b or MTS2) is a candidate tumor
suppressor with structural and functional similarity to
the p16 gene. This gene recognizes cyclin-dependent
kinases CDK4 and CDK6, and induces G1 arrest of the
cell cycle by competing with cyclin D for binding with
CDK4. Specific deletions of p15 sequences have been
found in only a few cases of leukemia and lymphomas.
In contrast, the p15 gene is preferentially hypermethy-
lated at a 5’-CpG island, which has been shown to be
associated with loss of transcription of this gene in leu-
kemia cells [9,10]. Furthermore, aberrant p15 methyla-
tion seems to have important prognostic implications
for risk assessment because patients with p15 methyla-
tion have overall shortened survival [11,12].
We have previously demonstrated that phenylhexyl
isothiocyanate (PHI), a man-made isothiocyanate, inhibits
histone deacetylases and remodels chromatins to induce
growth arrest in HL-60 myeloid leukemia cells in a concen-
tration-dependent manner[13]. Recent research has
described that this class of small chemicals, either present
naturally in cruciferous vegetables or man-made are poten-
tial chemopreventive agents. In animal models, PHI was
effective against tumorigenesis of esophagus, leukemia, and
carcinomas of lung and prostate[14-17]. The major
mechanism includes the induction of growth arrest and
apoptosis in tumor cells[18,19]. Since we have demon-
strated that PHI is an inhibitor of HDACs, its effects on
p15 activity in leukemia cells has been a subject of investi-
gation. In this paper we demonstrated that PHI has a dual
effect on DNA methylation and histone acetylation in leu-
kemic T cells Molt-4. The cross-talk on the DNA and chro-
matin resulted in demethylating the CpG island of p15,
which is inactivated due to hypermethylation, and recov-
ered the unmethylated p15 for transcriptional activation.
An inter-active mechanism, involving a down-regulation of
the enzymes DNMTs and up-regulating the histone acetyl-
transferase P300/CBP and histone acetylation, is revealed.
Methods
Cell cultures
PHI, greater than 98% pure, was purchased from LKT
Lab (St. Paul, MN). Human acute lymphatic leukemia
cell line Molt-4 was obtained from China Center for
Type Culture Collection (CCTCC). Cells were main-
tained in RPMI-1640 medium supplemented with 10%
heat-inactivated fetal calf serum and maintained at 37°C
in humidified atmosphere containing 5% CO2. Cells in
exponential growth were exposed to PHI prepared in
75% methanol[13] at various concentrations for 5 days.
The control cultures were supplemented with the
methanol-containing medium. Some cell cultures were
supplemented with 2 μM of 5-azacytidine (5-Aza), a
known inhibitor of DNA methylation, or 1 μMo fT r i -
chostatin A (TSA), a known inhibitor of histone deace-
tylases, at various concentrations.
Methylation specific PCR (MSP)
The genomic DNA from cultured cells was extracted and
modified by bisulfate treatment for MS-PCR analyses[20].
DNA from cell cultures under different conditions was
isolated with the Tissue/Cell Genomic DNA Isolation Kit
(Pearl, China), employing the Wizard DNA Clean-Up
System (Promega, USA), and amplified by PCR with two
sets of gene promoter specific primer pairs that recognize
the methylated (M) and the unmethylated (U) CpG sites.
The primers for the methylated form of p15 (148pb) were
gcgttcgtattttgcggtt (positive sense), and cgtacaataaccgaac-
gaccga (antisense). The primers for unmethylated form
(154 bp) were tgtgatgtgtttgtattttgtggtt (positive sense) and
ccatacaataaccaaacaaccaa (antisense). The amplification was
performed in an Mastercycler unit (Eppendorf) under the
program conditions as follows: 95°C for 5 min; then 40
cycles of 95°C for 45 sec, 60°C for 45 sec, 72°C for 45 sec;
and finally 10 min at 72°C. The PCR products were visua-
lized in GeneGenius (Syngene, British) by ethidium bro-
mide staining in 2% agarose gels.
Western blot analysis
The protein levels were determined by Western blot
analysis as described previously[21]. Briefly, total pro-
teins were prepared from each culture condition with a
lysis buffer containing protease inhibitors, and the
lysates collected after centrifugation at 4°C. The protein
content of the lysates was determined with the Bradford
protein assay. Protein lysate was subjected to SDS-
PAGE, electrotransferred to nitrocellulose membrane,
and immunoblotted with specific antibodies. The follow-
ing antibodies were used for immunoblotting: anti-
acetyl-histone H3 (lysines 9 and 14) (1:300 dilution,
Upstate), anti-acetyl-Histone H4 (lysines 5, 8, 12, and
16) (1:300 dilution, Upstate), and anti-300/CBP (1:300
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anti-rabbit with HRP conjugate secondary antibodies
were purchased from Santa Cruz (USA). The reaction
was visualized through the ECL system, and the protein
levels were quantified with the anti-b-actin protein esti-
mation assay.
Reverse Transcription-Polymerase Chain
Reaction (RT-PCR)
Total RNA was isolated using Trizol reagent (Invitro-
gen, USA) according to the manufacturer’si n s t r u c -
tions. One-microgram total RNA isolated was used for
the first-strand cDNA synthesis with Reverse Tran-
scription System (Promega, USA). cDNA was amplified
using specific primer for p15, DNMT1, DNMT3A,
DNMT3B in separate reactions (Table 1). b-actin was
used as a loading control to ensure that cDNA was
complete and Taq was deactivated in each reaction.
The PCR products were visualized in GeneGenius
(Syngene, British) by ethidium bromide staining in
1.6% agarose gels.
Statistical analysis
The data was analyzed by statistical software SPSS13.0.
Data measurement was presented as mean ± SD, from
multiple independent experiments by homogeneity test
for variance and test of normality. Results were evalu-
ated by One-way ANOVA between groups. P <0 . 0 5
was considered to be statistically significant.
Results
Demethylating p15 by PHI
The DNA methylation status of p15 in human lymphatic
leukemia T cells Molt-4 was evaluated by MS-PCR. Figure
1A showed the presence of methylated p15 (p15-M), and
the unmethylated p15 (p15-U) was undetectable. After
exposure of Molt-4 cells to PHI for 5 days, the methylated
p15 was decreased, with the magnitude in positive relation
to the PHI concentrations. The unmethylated p15 became
detectable, replacing the decrease of methylated p15. The
activity of 40 μM PHI to reverse p15 methylation was
similar to that of 2 μM of 5-Aza, a known inhibitor of
DNA methylation or 1 μM of TSA, which was shown in
endometrial cancer cells as a demethylating agent as it
reduced DNMT3B level and de novo DNMT activity[22].
The mRNA level of p15 in Molt-4 cells was examined
without or with the exposure to PHI. Figure 1B showed
the comparison of the levels of mRNA of p15 and b-actin.
I nt h ep r e s e n c eo fP H I ,t h ep15 mRNA expression was
enhanced in a concentration-dependent manner. The
ratios were: control (0.17 ± 0.12), PHI 10 μM( 0 . 2 9±
0.14), PHI 20 μM (0.55 ± 0.07), PHI 40 μM (0.93 ± 0.13),
TSA (0.65 ± 0.11), and 5-Aza (0.89 ± 0.13). The expression
levels of p15 mRNA mediated by PHI were statistically sig-
nificantly (P < 0.05) as compared to that without PHI
treatment. The protein expression of p15 was examined
by Western blotting in parallel. Figure 1C depicts
Table 1 PCR premiers for P15, DNMT1, DNMT3A, and
DNMT3B mRNA
sequence (5’-3’) extent
(bp)
anneal
temperature (°C)
actin1 F:gtggggcgccccaggcacca 517 Variable
R:ctccttaatgtcacgcacgatttc
actin2 F:ctacaatgagctgcgtgtggc 271 Variable
R:caggtccagacgcaggatggc
p15 F:tgggggcggcagcgatgag 451 56
R:aggtgggtgggggtgggaaat
DNMT1 F:accatcacatctcattttgc 238 56
R:ggtttgacttcggagtctct
DNMT3A F:cacacagaagcatatccaggagtg 551 55
R:agtggactgggaaaccaaataccc
DNMT3B F:aatgtgaatccagccaggaaaggc 190 55
R:actggattacactccaggaaccgt
F: Forward primer R: Reverse primer
cDNA was amplified using specific primer for, DNMT1
Figure 1 PHI reversed hypermethylation of p15 and induced
transcription activation. A: PHI induced p15 hypomethylation with
the decreasing of the methylated p15 (p15-M) and increase of the
unmethylated form of p15 (p15-U). MS-PCR was performed using
primers specific for p15-M and p15-U DNA forms of p15 as
described in the methods. 5-Aza (2 μM) and TSA (1 μM) were used
as controls for DNA hypomethylation. B: P15 mRNA levels were
enhanced by PHI treatment. The expression levels of p15 mRNA
were measured by RT-PCR. C: Up-regulation of p15 protein
expression by PHI. P15 protein levels were detected by Western
blotting, and b-actin was used as a loading control.
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after treatment with PHI at 20-40 μM, similar to the 5-
Aza effect. The results thus indicated that PHI might be a
potent methylation inhibitor for the CpG island of p15
gene, leading to reactivating p15 transcription in the leu-
kemic cells.
PHI decreased the expression of DNMT1, DNMT3B
The mRNA levels of the enzymes responsible for DNA
methylation, i.e., DNMT1, DNMT3A, DNMT3B, with-
out or with the exposure to PHI, were evaluated with
RT-PCR (Figure 2A). The gray scale of DNMTs was
contrasted to that of b-actin (Figure 2B), and demon-
s t r a t e dt h a tt h em R N Ao fD N M T 1a n dD N M T 3 Bw e r e
significantly decreased after exposure for to PHI for 5
days, in a concentration-dependent manner (P <0 . 0 5 ) .
The mRNA level of DNMT3A, on the other hand, was
not significantly altered under the same condition.
PHI induced histone acetylation and acetyltransferase
up-regulation
Molt-4 cells were exposed to PHI at various concentra-
tions. Figure 3A showed that after exposure of Molt-4
cells to PHI, the acetylation of histone H3 or H4 was sig-
nificantly increased in a concentration and time-depen-
dent manner. Acetylated histone H3 was elevated
approximately 1.13, 1.21 and 1.35-folds with PHI at 5, 20,
or 40 μM for 3 h, as compared to controls without PHI.
After 7 hours, acetylation was increased by 2.0, 2.2, 4.0-
folds. Similarly, acetylated histone H4 was increased
approximately 1.09, 1.45 and 1.72-folds after 3 hours, and
1.3, 1.8, 1.9-folds after 7 hours. The enzyme level of P300/
CBP was examined in parallel. Figure 3B showed that the
increase of P300/CBP could be clearly observed after
exposed to 5 μM or more PHI, similar to the effects on
histone acetylation. Approximately 1.1, 1.13 and 1.23-folds
increase of P300/CBP, over the control, was observed 3
hours after exposure to PHI at 5, 20 and 40 μM, and
approximately 1.38, 1.9 and 2.14-folds after 7 hours.
Discussion
DNA methylation and histone acetylation are two well
known epigenetic chromatin modifications. At least 80
clinical trials are underway, testing more than eleven
different HDAC inhibitory agents including both hema-
tological and solid malignancies [23-25]. This study
showed for the first time that PHI had dual effects on
enhancing histone acetylation as well as demethylating
p15. Upon exposure to PHI, the unmethylated p15,
otherwise absent, became detectable, along with the dis-
appearance of the methylated p15. This reversal of p15
methylation correlates with reexpression of p15.T h e
activity of PHI in demethylating p15 was shown to be
s i m i l a rt ot h a to f5 - A z aa n dT S A .T oo u rk n o w l e d g e ,
this study is the first to demonstrate that the hyper-
methylated p15 gene in leukemic T cells could be reacti-
vated by an isothiocyanate. Our analyses have provided
two inter-related mechanisms for hypomethylation of
p15. They are presented in the following.
One potential mechanism for initiating demethylation
of p15 by PHI could be that the expressions of the
DNA methylating enzymes were down-regulated. This
possibility was examined with the three DNA methylat-
ing enzymes DNMT1, DNMT3A, and DNMT3B. The
study showed that in the presence of PHI, the mRNA of
two of the enzymes, DNMT1 and DNMT3B, was signifi-
cantly down-regulated in a concentration-dependent
manner. The mRNA of the enzyme DNMT3A, however,
did not show a significant alteration. The expression of
DNMT3A is known to be ubiquitous and this has been
under investigation as a basis of this observation. The
results suggested that reduction of the DNMT1 and
DNMT3B expression and their activity could be a
responsible mechanism for hypomethylation of p15.
This interpretation is in line with the reports that
DNMTs are commonly over-expressed in leukemias.
AML cells with hypermethylated p15 tended to express
higher levels of DNMT1 and DNMT3B [5,6]. Melki et
al [5] demonstrated that the average expression of DNA
methyltransferase mRNA from the bone marrow cells of
Figure 2 Down-regulation of the DNA methylating enzymes by
PHI. A: The mRNA of DNMT1 and DNMT3B was down regulated by
PHI in concentration-dependent manner. B: Ratio of the gray scale
of DNMTs contrasted to that of b-actin.
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the expression of normal bone marrow. Mizuno[6]
found a mean increase of 5.3-, 4.4-, and 11.7-folds of
DNMT1, 3A, and 3B in AML, respectively, comparing
with the control bone marrow cells. Although CML
cells in the chronic phase did not show significant
changes, cells in the acute phase showed 3.2-, 4.5-, and
3.4- fold mean increases in the levels of DNMT1, 3A,
and 3B, respectively.
The major mechanism of the current hypomethylating
drugs, such 5-Azacytidine and decitabine, is their cova-
lent binding to the DNMTs, which resulting in the irre-
versible inhibition of the DNMT activity, leading to the
hypomethylation of the genomic DNA [26]. Our data
showed that PHI could reduce the synthesis of DNMTs.
It may be an additional mechanism for PHI to induce
DNA hypomethylation. Whether PHI also bind to
DNMTs remains to be investigated.
The methylation of p15 by PHI could also be related to
the PHI effects on histone acetylation. Histone acetyla-
tion generally correlates to an open and transcriptionally
active chromatin, whereas histone deacetylation is asso-
ciated with chromatin condensation and transcriptional
repression. The p15 CpG island region is surrounded
with both histone acetylated H3 and methylated H3K9 in
AML[27]. PHI could up-regulate the expression of acetyl-
transferase P300/CBP and induces the accumulation of
acetylated histone H3, H4 in Molt-4, resulting in chro-
matin unfolding and accessibility of regulators in the p15
promoter for transcriptional activation. This is consistent
with previous data showing that PHI was inhibitor of
HDACs [28].
Conclusion
PHI could induce DNA demethylation and acetylated
H3, H4 accumulation in Molt-4 cells. Hypermethylation
of gene p15 was reversed and p15 transcription could be
reactivated de novo by PHI.
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